Brief: Eton Pharmaceuticals Under Agreement, Co Pays Aquestive Upfront License Fee Of $10 Million - SEC Filing
14/10/2026 13:20
BRIEF-Eton Pharmaceuticals Under Agreement, Co Pays Aquestive Upfront License Fee Of $10 Million - SEC Filing Oct 14 (Reuters) - Eton Pharmaceuticals Inc ETON.O:
ETON PHARMACEUTICALS - UNDER AGREEMENT, CO PAYS AQUESTIVE UPFRONT LICENSE FEE OF $10 MILLION - SEC FILING
ETON PHARMACEUTICALS - TO PAY AQUESTIVE UP TO $47.50 MILLION IN MILESTONE PAYMENTS - SEC FILING
ETON PHARMACEUTICALS - TO PAY AQUESTIVE ROYALTIES AT MID-TEENS PERCENTAGE RATE ON LIBERVANT SALES - SEC FILING
ETON PHARMACEUTICALS - ENTERED INTO SUPPLY AGREEMENT WITH AQUESTIVE; AGREEMENT FOR LIBERVANT HAS INITIAL TERM OF 20 YEARS - SEC FILING
Source text: [ID:n0001437749-26-032600]
Further company coverage: ETON.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Eton Pharmaceuticals
See all newsBrief: Eton Pharmaceuticals Under Agreement, Co Pays Aquestive Upfront License Fee Of $10 Million - SEC Filing
Aquestive rises on US licensing deal for seizure drug with Eton Pharma
U.S. STOCKS ON THE MOVE-Sun Communities, Cisco Systems, Paysafe
U.S. STOCKS ON THE MOVE-Fox, Sun Communities, Reddit, drone firms
U.S. STOCKS ON THE MOVE-Boost Run, Nektar Therapeutics, Swarmer